{
    "clinical_study": {
        "@rank": "70605", 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the safety, tolerability and efficacy of\n      octaplasLG in pediatric patients who require replacement of multiple coagulation factors.\n      Replacement of multiple coagulation factors in pediatric patients with acquired deficiencies\n      due to liver disease and in pediatric patients requiring cardiac surgery or liver surgery."
        }, 
        "brief_title": "Open-label, Multicenter, Post-Marketing Requirement Study to Investigate Safety, Tolerability and Efficacy of octaplasLG in the Management of Pediatric Patients Who Require Replacement of Multiple Coagulation Factors", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Liver or Cardiac Surgery", 
            "Liver Dysfunction", 
            "Coagulopathy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Blood Coagulation Disorders", 
                "Hemostatic Disorders", 
                "Liver Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients requiring liver or cardiac surgery and/or patients with liver dysfunction\n             associated with coagulopathy in whom replacement of multiple coagulation factors is\n             required and plasma is ordered by the treating physician, or pre-operative PELD score\n             at least 15 for liver transplant or failure patients or pre-operative STAT score at\n             least 3 for cardiac surgery patients.\n\n          -  Voluntarily given, written and signed informed consent by the patient's legal\n             representative(s) or guardian(s). If the child is of an age deemed old enough by the\n             institution to understand the risks and benefits of the study, they should also be\n             made aware of the risks/benefits of the study and provide written assent.\n\n          -  Male or female patient 16 years of age or older.\n\n        Exclusion Criteria:\n\n          -  Patient with known homozygous congenital deficiency of protein S.\n\n          -  Patient has a history of hypersensitivity reaction to blood or plasma-derived\n             products or to any excipient of the investigational product.\n\n          -  Patient has an already known IgA deficiency with documented antibodies against IgA.\n\n          -  Patient has a congenital factor deficiency or platelet disorder requiring plasma\n             treatment.\n\n          -  Patient is currently participating in another study investigating a new drug product\n             or another interventional clinical study that may impact coagulation factors or has\n             participated during the last three (3) months.\n\n          -  Patient received FFP, FP24 or any other plasma product other than octaplasLG within\n             the last seven (7) days during this hospitalization.\n\n          -  Patient is on ECMO (Extracorporeal Membrane Oxygenation) when plasma is ordered by\n             the treating physician for the first infusion episode.\n\n          -  Patient is planned recipient for a living donor OLT.\n\n          -  Patient is pregnant.\n\n          -  Patient is predicted to require massive blood transfusion defined as more than 40 mL\n             per kilogram of all blood products in a 24-hour period\n\n          -  Patient is receiving plasma exchange, TPE or plasmapheresis.\n\n          -  Patient is a premature neonate defined as less than 37 weeks gestation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "16 Years", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients requiring liver or cardiac surgery and/or patients with liver dysfunction\n        associated with coagulopathy in whom replacement of multiple coagulation factors is\n        required and plasma is ordered by the treating physician, or pre-operative PELD score \u2265 15\n        for liver transplant or failure patients or pre-operative STAT score \u22653 for cardiac\n        surgery patients."
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02050841", 
            "org_study_id": "LAS-212"
        }, 
        "intervention": {
            "intervention_name": "octaplasLG", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pediatric", 
            "patients", 
            "replacement", 
            "coagulation factors"
        ], 
        "lastchanged_date": "January 30, 2014", 
        "number_of_groups": "1", 
        "official_title": "An Open-label, Multicenter, Post-Marketing Requirement (PMR) Study to Investigate the Safety, Tolerability and Efficacy of octaplasLG in the Management of Pediatric Patients Who Require Replacement of Multiple Coagulation Factors.", 
        "overall_contact": {
            "email": "Michael.Eppolito@octapharma.com", 
            "last_name": "Michael Eppolito, MBA", 
            "phone": "215-527-4374"
        }, 
        "overall_official": {
            "affiliation": "International Medical Director", 
            "last_name": "Wolfgang Frenzel", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Monitoring of adverse drug reactions (e.g., allergic reactions), TEs, TEEs and hyperfibrinolytic events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 6 days"
            }, 
            {
                "description": "Assessment of metabolic derangements, renal function and hematologic implications measurable by the following: Chem 7, CBC, calcium and ionized calcium.", 
                "measure": "Monitoring of clinically significant changes in laboratory parameters", 
                "safety_issue": "Yes", 
                "time_frame": "up to 6 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02050841"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Octapharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Octapharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}